Core Points - The National Healthcare Security Administration (NHSA) has issued a notice to strengthen monitoring and handling of "dual pricing" practices in designated retail pharmacies [1] - Recent reports indicate that some pharmacies are charging higher prices for the same medications to insured patients compared to uninsured patients, which constitutes price fraud [1] - The notice emphasizes the need for local healthcare departments to take responsibility and collaborate with market regulation authorities to conduct thorough inspections and investigations [1] Summary by Sections - Regulatory Actions - The NHSA has mandated a crackdown on discriminatory pricing practices in pharmacies, specifically targeting the "dual pricing" issue [1] - Legal frameworks such as the Price Law and the Drug Administration Law are cited as the basis for these actions against pharmacies [1] - Monitoring and Enforcement - Local healthcare departments are required to maintain ongoing monitoring and governance of pricing practices in pharmacies [1] - Measures for addressing violations include discussions with pharmacy management, suspension of insurance settlements, and potential legal actions [1] - Impact on Patients - The enforcement of these regulations aims to protect the rights of patients and ensure fair pricing for medications, thereby safeguarding public trust in the healthcare system [1]
部分药店对医保非医保患者采取阴阳价格 国家医保局要求严查
Ren Min Ri Bao·2025-10-13 23:18